GlassScriptPhysician profile
Aida L Ramos
NPI 1255574307
$9,067.15
in general payments reported to CMS, 2019-2025
38 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,200 · 2022: $1,972 · 2023: $2,134 · 2024: $1,317 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,875 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,875.13 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,453.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $879.57 | 2021-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.04 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $749.39 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $731.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $685.78 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $652.14 | 2021-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $487.46 | 2023-2025 | |
| Novo Nordisk INC | $427.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $384.95 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $271.47 | 2022-2023 | |
| Pfizer INC. | $259.08 | 2021-2025 | |
| Amarin Pharma, INC. | $211.75 | 2021-2022 | |
| Gilead Sciences, INC. | $123.01 | 2021 | |
| Merck Sharp & Dohme LLC | $115.35 | 2021-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.